Last reviewed · How we verify

Midazolam and fentanyl

Corewell Health East · FDA-approved active Small molecule

Midazolam and fentanyl together provide sedation and analgesia by enhancing GABAergic inhibition in the central nervous system and activating opioid receptors, respectively.

Midazolam is a benzodiazepine that enhances GABA inhibitory signaling in the central nervous system, while fentanyl is an opioid agonist that binds mu opioid receptors to produce analgesia and sedation. Used for Procedural sedation and analgesia, Conscious sedation for diagnostic and therapeutic procedures.

At a glance

Generic nameMidazolam and fentanyl
Also known asVersed (Midazolam), Fentanyl Citrate Injection, USP (Fentanyl), Versed, Sublimaze
SponsorCorewell Health East
Drug classBenzodiazepine and opioid combination
TargetGABA-A receptor (midazolam); mu opioid receptor (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesia/Sedation
PhaseFDA-approved

Mechanism of action

Midazolam is a benzodiazepine that potentiates GABA-A receptor signaling to produce sedation, anxiolysis, and amnesia. Fentanyl is a synthetic opioid agonist at mu-opioid receptors that produces analgesia and respiratory depression. This combination is used for procedural sedation and anesthesia, where the synergistic effects provide both pain relief and sedation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: